Research Topics
| Vincenzo CalleaSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucilFortunato Morabito
Haematologica 87:217-8. 2002....- Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapyVincenzo Callea
Hematology Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
Leuk Lymphoma 47:2314-20. 2006..In conclusion, SN development is dependent on the length of follow-up rather than on therapy duration. F + C should be administered with caution after prolonged CLB therapy... - Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patientsMassimo Martino
Department of Bone Marrow Transplant, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
Eur J Haematol 78:35-40. 2007..1% to 76.5%). In conclusion, Thal as maintenance therapy after double ASCT is associated with low feasibility and high toxicity and could prevent a lengthy use of this antineoplastic agent... - High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patientsMassimo Martino
Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
Am J Hematol 81:973-8. 2006..In conclusion, an up-front tandem strategy with a very low reduced intensity-conditioning regimen for allografting following autografting is feasible and induces high CR/nCR rate in MM... 
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMAFortunato Morabito
Unità Operativa di Ematologia, Azienda Ospedaliera dell Annunziata, 87100 Cosenza, Italy
Eur J Haematol 84:223-8. 2010..In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI...- Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphomaEmilio Iannitto
Hematology and BMT Unit, Department of Oncology, University of Palermo, Palermo, Italy
Eur J Haematol 76:134-40. 2006..The purpose of the present study was to estimate the standardised incidence ratio (SIR) and the absolute excess risk (AER) of SPC in patients with splenic marginal zone lymphoma (SMZL)... - Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trialEmilio Iannitto
Divisione di Ematologia e Trapianto di Midollo Osseo, Policlinico P Giaccone, Palermo, Italy
Clin Lymphoma Myeloma 9:138-44. 2009.... - Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemiaFortunato Morabito
Unità Operativa Complessa di Ematologia, Azienda Ospedaliera, Cosenza, Italy
Br J Haematol 146:44-53. 2009..8, 95% confidence interval (CI) 2.4-5.8] and high-risk group (HR = 8.0, 95% CI 3.9-16.2). Specific transcriptional patterns were significantly associated with risk groups... - Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano LinformiFortunato Morabito
Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
Cancer 101:1601-8. 2004..To assess the impact of T-cell/B-cell phenotype on clinical outcome, the authors retrospectively compared patients who had peripheral T-cell lymphoma, unspecified (PTCL-U), with patients who had diffuse large B-cell lymphoma (DLBCL)... - Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myelomaFortunato Morabito
Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
Haematologica 87:1192-9. 2002..Furthermore, there are considerable concerns regarding the appropriate use of health care resources in order to reduce costs associated with PBSCT. One of the strategies attempted to reach this goal is outpatient-based PBSCT... - Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitroFortunato Morabito
Dipartimento di Ematologia Azienda, Ospedaliera Bianchi-Melacrino, Reggio Calabria, Italy
Haematologica 88:864-73. 2003..Some of the data obtained also suggest a use for CD10 to monitor apoptosis of B-CLL in a clinical setting... - Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaAntonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera AO S Giovanni Battista, Turin, Italy
Blood 109:2767-72. 2007..Initial results showed that VMPT is an effective salvage therapy with a very high proportion of responses. The incidence of neurotoxicities was unexpectedly low... - Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialAntonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Blood 112:3107-14. 2008..34). These data confirm activity of MPT for PFS but failed to show any survival advantage. New agents in the management of relapsed disease could explain this finding. The study is registered at www.clinicaltrials.gov as #NCT00232934... - Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialAntonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy
Lancet 367:825-31. 2006..This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years... - Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
Blood 107:4643-9. 2006..In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient... - Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survivaMarco Ladetto
Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
Blood 111:4004-13. 2008..This trial was registered at www.clinicaltrials.gov as no. NCT00435955... - Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialAntonio Palumbo
, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
Blood 104:3052-7. 2004..Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients... - Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaAntonio Palumbo
, Azienda Ospedaliera S. Giovanni Battista, Turin, Italy
Cancer 104:1428-33. 2005..Administration of prophylactic anticoagulant was required to prevent thromboembolism. MPT merits further investigation in randomized clinical trials... - The clinical value of tumor burden at diagnosis in Hodgkin lymphomaPaolo G Gobbi
Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
Cancer 101:1824-34. 2004..The authors investigated the clinical role of tumor burden (TB) in patients with Hodgkin lymphoma, relating this parameter to most of the current clinical and prognostic factors and to the best predictive multifactorial models... - A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemiaStefano Molica
Medical Oncology Unit, Department of Oncology and Hematology, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy
Leuk Lymphoma 46:553-60. 2005.... - Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantationSara Galimberti
Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S Chiara Via Roma, 56 56100 Pisa, Italy
Leuk Res 29:961-6. 2005..01). These data sustain the relevant role of molecular monitoring in MM patients undergoing NMT. MRD monitoring would assist physicians in making additional therapeutic decisions to better control this hematological malignancy... - Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patientsMassimo Martino
Bone Marrow Transplantation Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, 89100, Reggio, Calabria, Italy
Support Care Cancer 13:182-7. 2005..008). Independently of Hb levels at PBSCT, rHuEPO therapy was significantly associated with a lower risk of transfusion requirement. In conclusion, rHuEPO is shown to be effective when administered prior to high-dose therapy in MM... - Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analysesSonia Fabris
Laboratorio di Ematologia Sperimentale e Genetica Molecolare, UO Ematologia 1, Dipartimento di Scienze Mediche, , Ospedale Maggiore IRCCS, Milan, Italy
Genes Chromosomes Cancer 42:117-27. 2005..Our data suggest the importance of using combined molecular cytogenetic and gene expression approaches to detect genetic aberrations in MM... - Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myelomaMichela Mattioli
Laboratorio di Ematologia Sperimentale e Genetica Molecolare and U.O. Ematologia 1, Dipartimento di Scienze Mediche, , Ospedale Maggiore IRCCS, Milano, Italy
Oncogene 24:2461-73. 2005.... - Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring systemLuca Baldini
Unità Operativa Ematologia 1, Dipartimento di Ematologia e Oncologia, Ospedale Maggiore, I R C C S, Milano, Italy
J Clin Oncol 23:4662-8. 2005.... - IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemiaDavide Bagnara
Department of Experimental Medicine, Human Anatomy Section, University of Genoa, Genoa, Italy
Br J Haematol 133:50-8. 2006..We conclude that antigen stimulation and somatic hypermutation may participate in disease progression through the selection and expansion of neoplastic subclone(s)... - Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocationsLuca Agnelli
UO Ematologia 2, Centro G. Marcora, Ospedale Maggiore Policlinico IRCCS, Dipartimento Scienze Mediche, , Via Francesco Sforza 35, 20122 Milano, Italy
J Clin Oncol 23:7296-306. 2005..The identification of a distinctive gene expression pattern in TC2 patients may improve risk stratification and indicate novel therapeutic targets...